Payment overview · 2025
General Payments
$415.92
13 reported records · 5 companies
Healthcare provider profile · identity verified
Michael G Wiggins, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · VIDALIA, GA · NPI 1528040326
Verified facts
What the public records show
CMS Open Payments records show Michael G Wiggins, FNP received $415.92 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viibryd by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexlizet by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.35 | 33.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $105.34 | 25.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.87 | 21.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.87 | 15.1% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.49 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.92 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $105.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $65.60 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.87 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $12.36 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $12.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 415 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 291 | 75 |
| Cefuroxime | Cefuroxime Axetil | 268 | 168 |
| Gabapentin | Gabapentin | 264 | 60 |
| Potassium Chloride | Potassium Chloride | 251 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 227 | 58 |
| Omeprazole | Omeprazole | 219 | 54 |
| Allopurinol | Allopurinol | 209 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 203 | 42 |
| Furosemide | Furosemide | 199 | 59 |
| Glipizide Er | Glipizide | 181 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 36 |
| Losartan Potassium | Losartan Potassium | 154 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 32 |
| Famotidine | Famotidine | 148 | 37 |
| Metformin Hcl | Metformin Hcl | 138 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 40 |
| Lisinopril | Lisinopril | 128 | 27 |
| Fluconazole | Fluconazole | 115 | 71 |
| Simvastatin | Simvastatin | 101 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 98 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 97 | 57 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 24 |
| Eliquis | Apixaban | 85 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 18 |
| Dexamethasone | Dexamethasone | 81 | 60 |
| Meloxicam | Meloxicam | 80 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 13 |
| Mounjaro | Tirzepatide | 76 | suppressed |
| Ozempic | Semaglutide | 76 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 59 |
| Ondansetron Odt | Ondansetron | 71 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 13 |
| Meclizine Hcl | Meclizine Hcl | 65 | 31 |
| Memantine Hcl | Memantine Hcl | 65 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 44 |
| Azithromycin | Azithromycin | 63 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 15 |
| Finasteride | Finasteride | 61 | 14 |
| Estradiol | Estradiol | 60 | 14 |
| Rabeprazole Sodium | Rabeprazole Sodium | 60 | 21 |
| Glipizide | Glipizide | 59 | 14 |
| Carvedilol | Carvedilol | 58 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Lovastatin | Lovastatin | 56 | suppressed |
| Mupirocin | Mupirocin | 54 | 36 |
| Megestrol Acetate | Megestrol Acetate | 51 | 13 |
| Jardiance | Empagliflozin | 50 | 11 |
| Chlorthalidone | Chlorthalidone | 49 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 13 |
| Ezetimibe | Ezetimibe | 45 | 11 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 15 |
| Spironolactone | Spironolactone | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 25 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 25 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 12 |
| Colchicine | Colchicine | 30 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 18 |
| Metronidazole | Metronidazole | 26 | 18 |
| Primidone | Primidone | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Valsartan | Valsartan | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | 11 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | 12 |
| Torsemide | Torsemide | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Viibryd | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.92 · 13 records | Novo Nordisk Inc | EVENITY, INSPIRE, KRYSTEXXA, NEXLETOL, Ozempic, PROLIA, QULIPTA, Rybelsus, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error